Evidence map›Paper›PMID 36973425›Full record

ArticleCancer gene therapy2023

Immuno-regulatory malignant B cells contribute to Chronic Lymphocytic Leukemia progression.

Arsène Mékinian, Anne Quinquenel, Koceïla Ait Belkacem, Feriel Kanoun, Elisabetta Dondi, Emilie Franck, Marouane Boubaya, Maïssa Mhibik, Fanny Baran-Marszak, Rémi Letestu and 4 more

Open access · hybridAbstract read
In one paragraph

Article in Cancer gene therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Analysis of Mutational Status ofInternational journal of molecular sciences · 2024
    Article
  5. Targeting T regulatory (TCancer drug resistance (Alhambra, Calif.) · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Arsène MékinianINSERM, U978, Bobigny, France.
Anne Quinquenel *INSERM, U978, Bobigny, France.
Koceïla Ait Belkacem *INSERM, U978, Bobigny, France.
Feriel KanounINSERM, U978, Bobigny, France.
Elisabetta DondiINSERM, U978, Bobigny, France.
Emilie FranckINSERM, U978, Bobigny, France.
Marouane BoubayaURC, APHP, Hôpital Avicenne, Bobigny, France.
Maïssa MhibikINSERM, U978, Bobigny, France.
Fanny Baran-MarszakINSERM, U978, Bobigny, France.ORCID 0000-0002-3723-2927
Rémi LetestuINSERM, U978, Bobigny, France.
Florence Ajchenbaum-CymbalistaINSERM, U978, Bobigny, France.
Vincent LévyURC, APHP, Hôpital Avicenne, Bobigny, France.
Nadine Varin-BlankINSERM, U978, Bobigny, France. nadine.varin@inserm.fr.
Christine Le RoyINSERM, U978, Bobigny, France. christine.le-roy@inserm.fr.ORCID 0000-0003-3538-6487
Inserm · FRHôpital Avicenne · FRDélégation Paris 5 · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic Lymphocytic Leukemia (CLL) is a heterogeneous B cell neoplasm ranging from indolent to rapidly progressive disease. Leukemic cell subsets with regulatory properties evade immune clearance; however, the contribution of such subsets during CLL progression is not completely elucidated. Here, we report that CLL B cells crosstalk with their immune counterparts, notably by promoting the regulatory T (Treg) cell compartment and shaping several helper T (Th) subsets. Among various constitutively- and BCR/CD40-mediated factors secreted, tumour subsets co-express two important immunoregulatory cytokines, IL10 and TGFβ1, both associated with a memory B cell phenotype. Neutralizing secreted IL10 or inhibiting the TGFβ signalling pathway demonstrated that these cytokines are mainly involved in Th- and Treg differentiation/maintenance. In line with the regulatory subsets, we also demonstrated that a CLL B cell population expresses FOXP3, a marker of regulatory T cells. Analysis of IL10, TGFβ1 and FOXP3 positive subpopulations frequencies in CLL samples discriminated 2 clusters of untreated CLL patients that were significantly different in Tregs frequency and time-to-treatment. Since this distinction was pertinent to disease progression, the regulatory profiling provides a new rationale for patient stratification and sheds light on immune dysfunction in CLL.

Indexed as

Leukemia, Lymphocytic, Chronic, B-CellCytokinesForkhead Transcription FactorsHumansInterleukin-10T-Lymphocytes, RegulatoryCytokinesForkhead Transcription FactorsInterleukin-10

Identifiers

PMID36973425
PMCPMC10353928
OpenAlexW4318717142

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.